Brad L. Tade - 19 Feb 2025 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
CFO and Treasurer
Signature
/s/ Brad L. Tade, by Adam S. Grossman as Attorney-in-fact
Issuer symbol
ADMA
Transactions as of
19 Feb 2025
Transactions value $
$0
Form type
4
Filing time
21 Feb 2025, 21:01:55 UTC
Previous filing
22 Nov 2024
Next filing
27 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Award $0 +62.2K +31.2% $0.00 262K 19 Feb 2025 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Stock Option (right to buy) Award $0 +93K $0.00 93K 19 Feb 2025 Common Stock 93K $16.07 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date.
F2 Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;
F3 (continued from footnote 2) (iii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;
F4 (continued from footnote 3) (iv) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (v) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs.
F5 The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan.